NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...

These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...

About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. The wearable device has earned FDA clearance for its medical applications, ...

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...